Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Axsome Therapeutics Inc AXSM

Healthcare Biotechnology
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor... see more

Recent & Breaking News (NDAQ:AXSM)

Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Major Depressive Disorder

GlobeNewswire March 27, 2019

58 Biggest Movers From Yesterday

Benzinga.com  March 27, 2019

The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs

Benzinga.com  March 26, 2019

52 Biggest Movers From Yesterday

Benzinga.com  March 26, 2019

48 Stocks Moving In Thursday's Mid-Day Session

Benzinga.com  March 21, 2019

The Daily Biotech Pulse: FDA Nod For Sage's Postpartum Depression Drug, Pfizer Invests In Gene Therapy Company

Benzinga.com  March 20, 2019

70 Biggest Movers From Yesterday

Benzinga.com  March 20, 2019

Mid-Afternoon Market Update: U.S. Stocks Turn Lower; Blucora Shares Spike Higher

Benzinga.com  March 19, 2019

The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering

Benzinga.com  March 14, 2019

Axsome Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

GlobeNewswire March 14, 2019

Axsome Therapeutics Secures $24 Million Growth Capital Loan Facility Led by Silicon Valley Bank

GlobeNewswire March 6, 2019

Axsome Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results on March 14, 2019

GlobeNewswire March 5, 2019

Axsome Therapeutics Initiates MOMENTUM Phase 3 Trial of AXS-07 in Migraine

GlobeNewswire March 4, 2019

The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering

Benzinga.com  February 6, 2019

Axsome Therapeutics Receives FDA Agreement under Special Protocol Assessment (SPA) for the MOMENTUM Phase 3 Trial of AXS-07 in Migraine

GlobeNewswire February 6, 2019

The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results

Benzinga.com  February 5, 2019

Axsome Therapeutics Initiates Phase 2 Trial of AXS-12 in Narcolepsy

GlobeNewswire January 30, 2019

28 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  January 23, 2019

40 Stocks Moving In Friday's Pre-Market Session

Benzinga.com  January 18, 2019

40 Stocks Moving In Thursday's Mid-Day Session

Benzinga.com  January 10, 2019